Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
Iron overload sometimes complicates the clinical course of bone marrow transplantation and can cause damage to liver and heart function. A patient with post-transplantation secondary hemochromatosis was treated with deferasirox, which not only normalized ferritin levels, but also reduced hepatic iron to normal values as measured by biosusceptometry with a superconducting quantum interference device. Side effects were minimal. The use of deferasirox to reduce post-transplant iron burden merits evaluation in a larger patient population.
Hematology Department, 'A. Perrino' Hospital, Brindisi, Italy. antonella.quarta@gmail.com
A
A
Quarta
A
A
Melpignano
G
G
Quarta
D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications* / Q000628:therapy; D001565:Benzoates / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D000077588:Deferasirox; D005293:Ferritins / Q000097:blood; D006432:Hemochromatosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy; D008297:Male; D014230:Triazoles / Q000627:therapeutic use*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D007501:Iron; D000077588:Deferasirox